Abstract ND06: ECI830, a potent and highly selective CDK2 inhibitor, for the treatment of HR+/HER2− breast cancer and <i>CCNE1</i> -amplified tumorsSamuel Ho, Vivek Rauniyar, Bradley French et al.|Cancer Research|2026Cited by 0